Swedish Orphan Biovitrum

Update in progress

SOBI.ST (Stockholm)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Swedish Orphan Biovitrum AB (publ) is a Stockholm-based biopharma developing medicines for haematology, immunology and specialty care across Europe, North America, the Middle East, Asia and Australia. It operates in three segments and markets drugs including Alprolix, Elocta/Eloctate, ALTUVOCT, Aspaveli/Empaveli, Doptelet, Gamifant, Kineret, Orfadin, Synagis and Zynlonta, plus others. It collaborates with Sanofi, Apellis, ADC Therapeutics and Cartesian Therapeutics. Founded 1939.

Company score

Sentiment: 0.43; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.27; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.27; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive